


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (Canceled).

Claim 7 (Currently amended). A compound of formula I



diastereomers, enantiomers or salts thereof

where

R₁ is hydrogen or R₆;

R_{1ab} and R_{1ac} are independently hydrogen, R₆ or -OR₆;

R_{1ad} is hydrogen;

one of R₂ or R₃ is hydrogen or alkyl and the other R₂ or R₃ is -Z₄-R_{6a}, where: Z₄ is -Z₁₁-C(O)-Z₁₂-

and R_{6a} is aryl optionally substituted with one or more Z₁, Z₂ or Z₃;

R₆ is alkyl;

R₁, R_{1ab}, R_{1ac} and R_{1ad} are independently

(1) — hydrogen or R₆;

(2) — OH or -OR₆;

(3) — SH or -SR₆;

(4) — C(O)_qH, C(O)_qR₆, or -O-C(O)_qR₆, where q is 1 or 2,

(5) — SO₃H or -S(O)_qR₆;

(6) — halo;

(7) — cyano;

(8) — nitro;

(9) — $Z_4-NR_7R_8$;

(10) — $Z_4-N(R_9)-Z_5-NR_{10}R_{11}$;

(11) — $Z_4-N(R_{12})-Z_5-R_6$, or

(12) — $P(O)(OR_6)_2$;

R_2 and R_3 are each independently H, Z_4-R_{6a} , or $Z_4-NR_{7a}R_{8a}$;

R_6 , R_{6a} , and R_{6b} are independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclo, or heterocycloalkyl, each of which is unsubstituted or substituted with Z_1 , Z_2 and one or more groups Z_3 ;

R_{7a} , R_{8a} , R_9 , R_{10} , R_{11} and R_{12}

(1) are each independently hydrogen, or Z_4R_{6b} ; or

(2) R_{7a} and R_{8a} may together be alkylene, alkenylene, or heteroalkylene, completing a 3 to 8 membered saturated or unsaturated ring with the nitrogen atom to which they are attached, which ring is unsubstituted or substituted with Z_1 , Z_2 and one or more groups Z_3 ; or

(3) any two of R_9 , R_{10} and R_{11} may together be alkylene, alkenylene or heteroalkylene completing a 3 to 8 membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z_1 , Z_2 and Z_3 ;

X_2 is $[[CZ_{3a}]]NZ_{3a}[[O \text{ or } S]]$;

Z_{3a} is $-C(O)_qZ_{6a}$, where q is 1 H, hydroxy, optionally substituted alkyl, optionally substituted heterocyclo, optionally substituted aryl, optionally substituted aralkyl, $-OZ_6$, $-C(O)_qH$, $-C(O)_qZ_{6a}$, $-Z_4-NZ_7Z_8$, or $-Z_4-N(Z_{10})-Z_5-Z_6$;

n is 1 to 3 2;

m is zero to 2 1;

Z_1 and Z_2 are hydrogen;

Z_3 is $-Z_4-NZ_7Z_8$, where Z_4 is alkyl;

Z_1 , Z_2 and Z_3 are each independently

(1) — hydrogen or Z_6 ;

(2) — ~~OH or OZ_6 ;~~(3) — ~~SH or SZ_6 ;~~(4) — ~~$\text{C}(\text{O})_q\text{H}$, $\text{C}(\text{O})_q\text{Z}_6$, or $\text{O}-\text{C}(\text{O})_q\text{Z}_6$, where q is 1 or 2,~~(5) — ~~SO_3H , $\text{S}(\text{O})_q\text{Z}_6$, or $\text{S}(\text{O})_q\text{N}(\text{Z}_9)\text{Z}_6$;~~(6) — ~~halo;~~(7) — ~~cyano;~~(8) — ~~nitro;~~(9) — ~~$\text{Z}_4-\text{NZ}_7\text{Z}_8$;~~(10) — ~~$\text{Z}_4-\text{N}(\text{Z}_9)-\text{Z}_5-\text{NZ}_7\text{Z}_8$;~~(11) — ~~$\text{Z}_4-\text{N}(\text{Z}_{10})-\text{Z}_5-\text{Z}_6$;~~(12) — ~~$\text{Z}_4-\text{N}(\text{Z}_{10})-\text{Z}_5-\text{H}$;~~(13) — ~~oxo;~~(14) — ~~any two of Z_1 , Z_2 , and Z_3 on a given substituent may together be alkylene or alkenylene completing a 3 to 8 membered saturated or unsaturated ring together with the atoms to which they are attached; or~~(15) — ~~any two of Z_1 , Z_2 , and Z_3 on a given substituent may together be $\text{O}-(\text{CH}_2)_q-\text{O}$;~~ ~~Z_4 and Z_5 are each independently~~(1) — ~~a single bond;~~(2) — ~~$\text{Z}_{11}-\text{S}(\text{O})_q-\text{Z}_{12}$;~~(3) — ~~$\text{Z}_{11}-\text{C}(\text{O})-\text{Z}_{12}$;~~(4) — ~~$\text{Z}_{11}-\text{C}(\text{S})-\text{Z}_{12}$;~~(5) — ~~$\text{Z}_{11}-\text{O}-\text{Z}_{12}$;~~(6) — ~~$\text{Z}_{11}-\text{S}-\text{Z}_{12}$;~~(7) — ~~$\text{Z}_{11}-\text{O}-\text{C}(\text{O})-\text{Z}_{12}$;~~(8) — ~~$\text{Z}_{11}-\text{C}(\text{O})-\text{O}-\text{Z}_{12}$; or~~(9) — ~~alkyl~~ ~~Z_6 and Z_{6a} is alkyl; are independently~~(i) — ~~alkyl, hydroxyalkyl, alkoxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, alkylaryl, cycloalkylaryl, heterocyclo, or heterocycloalkyl;~~

(ii) ~~a group (i) which is itself substituted by one or more of the same or different groups (i);~~
or

(iii) ~~a group (i) or (ii) which is independently substituted by one or more of the groups (2) to (15) of the definition of Z₁;~~

Z₇ and Z₈ are each independently hydrogen or -Z₄-Z_{6a}, where Z₄ is a single bond;

Z₇, Z₈, Z₉ and Z₁₀

~~(1) are each independently hydrogen or -Z₄-Z_{6a};~~

~~(2) Z₇ and Z₈ may together be alkylene, alkenylene, or heteroalkylene completing a 3- to 8-membered saturated or unsaturated ring together with the atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z₁, Z₂ and Z₃; or~~

~~(3) Z₇ or Z₈, together with Z₉, may be alkylene, alkenylene, or heteroalkylene completing a 3- to 8-membered saturated or unsaturated ring together with the nitrogen atoms to which they are attached, which ring is unsubstituted or substituted with one or more Z₁, Z₂ and Z₃;~~

Z₁₁ and Z₁₂ are each independently a single bond.


~~(1) — a single bond,~~

~~(2) — alkylene,~~

~~(3) — alkenylene, or~~

~~(4) — alkynylene;~~

Claim 8 (Previously presented). A compound of claim 7 having the formula



Claim 9 (Currently amended). A compound of claim 8 where

R₂ is hydrogen or alkyl; and

R₃ is -Z₄R_{6a}, where: Z₄ is -C(O)- and R_{6a} is aryl optionally substituted with one or more Z₁, Z₂, or Z₃.

~~(a) Z_4 is a single bond and R_{6a} is heteroaryl optionally substituted with one or more Z_1 , Z_2 or Z_3 ;~~

~~(b) Z_4 is $C(O)$ and R_{6a} is~~

~~(1) aryl optionally substituted with one or more Z_1 , Z_2 or Z_3 ;~~

~~(2) alkyl optionally substituted with one or more Z_1 , Z_2 or Z_3 ;~~

~~(3) cycloalkyl optionally substituted with one or more Z_1 , Z_2 or Z_3 ; or~~


~~(4) heterocyclo optionally substituted with one or more Z_1 , Z_2 or Z_3 ; or~~

~~(c) Z_4 is $C(O)O$ and R_{6a} is alkyl, cycloalkyl, aryl or aralkyl, any of which may be optionally substituted with one or more Z_1 , Z_2 or Z_3 .~~

Claim 10 (Currently amended). A compound of claim 9 wherein R_{1ab} ~~[[,]]~~ and R_{1ac} and R_{1ad} are independently H ~~[[,]]~~ or alkyl ~~[[,]]~~ hydroxy, nitro, halo, OR_6 , NR_7R_8 , $C(O)_qH$ or $C(O)_qR_6$.

Claim 11 (Original). A compound of claim 10 wherein R_{1ab} and R_{1ac} are independently alkyl.

Claim 12 (Currently amended). A compound of claim 8 having the following formula



where one of R_{1ab} ~~[[,]]~~ and R_{1ac} and R_{1ad} is H and the other is alkyl or OR_6 ~~two are independently alkyl, hydroxy, nitro, halo, OR_6 , NR_7R_8 , $C(O)_qH$ or $C(O)_qR_6$.~~

Claim 13 (Currently amended). A compound of claim 12 wherein one of R_{1ab} ~~[[,]]~~ and R_{1ac} and R_{1ad} is H and the other is two are independently alkyl or OR_6 .

Claim 14 (Previously presented). A compound of claim 13 wherein R_{1ac} is H.

Claim 15 (Canceled).

Claim 16 (Canceled)

Claim 17 (Previously presented). A pharmaceutical composition comprising at least one compound of claim 7 and a pharmaceutically acceptable vehicle or carrier therefor.

Claim 18 (Original). A pharmaceutical composition of claim 17 further comprising at least one additional therapeutic agent selected from anti-inflammatory agents, anti-proliferative agents, anti-cancer agents or anti-cytotoxic agents.

Claim 19 (Original). A pharmaceutical composition of claim 18 wherein the additional therapeutic agents are selected from steroids, mycophenolate mofetil, LTD₄ inhibitors, CTLA4-Ig, LEA-29Y, phosphodiesterase inhibitors, antihistamines, or p³⁸ MAPK inhibitors.

Claim 20 (Withdrawn). A method of treating a Tec family tyrosine kinase-associated disorder comprising the step of administering to a patient in need thereof, an effective amount of at least one compound of claim 1.

Claim 21 (Withdrawn). The method of claim 20 wherein the Tec family tyrosine kinase-associated disorder is an Emt-associated disorder.

Claim 22 (Withdrawn). The method of claim 21 wherein the Emt-associated disorder is selected from transplant rejection, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus, graft vs. host disease, T-cell mediated hypersensitivity disease, psoriasis, Hashimoto's thyroiditis, Guillain-Barre syndrome, cancer, contact dermatitis, allergic disease, asthma, ischemic or reperfusion injury, atopic dermatitis, allergic rhinitis, or chronic obstructive pulmonary disease.

Claim 23 (New). A method of treating a Tec family tyrosine kinase-associated disorder comprising the step of administering to a patient in need thereof, an effective amount of at least one compound of claim 7.

Claim 24 (New). The method of claim 23 wherein the Tec family tyrosine kinase-associated disorder is an Emt-associated disorder.

Claim 25 (New). The method of claim 24 wherein the Emt-associated disorder is selected from transplant rejection, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, lupus, graft vs. host disease, T-cell mediated hypersensitivity disease, psoriasis, Hashimoto's thyroiditis, Guillain-Barre syndrome, cancer, contact dermatitis, allergic disease, asthma, ischemic or reperfusion injury, atopic dermatitis, allergic rhinitis, or chronic obstructive pulmonary disease.